Catheter Precision's VIVO Is Now Eligible For National Reimbursement In The U.K.
Portfolio Pulse from Benzinga Newsdesk
Catheter Precision's VIVO, a cardiac mapping system, is now eligible for national reimbursement in the U.K. This could potentially increase the product's sales and usage in the country.
October 12, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catheter Precision's product VIVO is now eligible for national reimbursement in the U.K. This could potentially increase the product's sales and usage, positively impacting VTAK's revenues.
The eligibility for national reimbursement in the U.K. for Catheter Precision's VIVO could lead to increased sales and usage of the product in the country. This could potentially increase VTAK's revenues, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100